Phaarmasia Limited

PHRMASI6

INE486I01016

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:57 04/07/2024 pm IST			5-day change	1st Jan Change
54.65 ^INR	+1.79%		-6.82%	+38.81%

25/05	Phaarmasia Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
25/05	Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Phaarmasia Limited Appoints N.E.V Prasad Rao as the Chief Financial Officer

February 12, 2016 at 05:35 pm IST

Phaarmasia Limited at the board of directors meeting held on February 12, 2016 has appointed Mr. N.E.V Prasad Rao as the Chief Financial Officer of the company with the immediate effect from February 12, 2016.

Latest news about Phaarmasia Limited

Phaarmasia Limited Reports Earnings Results for the Full Year Ended March 31, 2024	25/05	CI
Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	25/05	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11	CI
Phaarmasia Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Phaarmasia Limited Reports Earnings Results for the Full Year Ended March 31, 2023	25/23/25	CI
Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	25/23/25	CI
Phaarmasia Limited Announces the Resignation of Maneesh Ramakant Sapte as Managing Director	31/23/31	CI
Maneesh Pharmaceuticals Limited canceled the acquisition of a 26.48658% stake in Phaarmasia Limited.	21/23/21	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/23/13	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Maneesh Pharmaceuticals Limited made an offer to acquire 26.48658% stake in Phaarmasia Limited for INR 45.2 million.	11/22/11	CI
Phaarmasia Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/22/12	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	10/22/10	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	09/21/09	CI
Phaarmasia Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	06/21/06	CI
Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	25/21/25	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	13/20/13	CI
Phaarmasia Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	15/20/15	CI
Phaarmasia Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	30/20/30	CI
Phaarmasia Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	13/20/13	CI
Phaarmasia Limited Announces Company Secretary and Compliance Changes	03/20/03	CI
Phaarmasia Limited Announces Executive Changes	05/19/05	CI
Phaarmasia Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	14/19/14	CI

Chart Phaarmasia Limited

Duration

Period

More charts

Company Profile

Phaarmasia Limited is an India-based company, which is primarily engaged in the manufacturing and sale of oral contraceptive pills (OCPâs). The Company manufactures and markets oral contraceptive tablets with various therapeutic dosage combinations along with iron tablets for the Ministry of Health & Family Welfare and for exports. Its product categories include hormone products and herbal products. Its hormone products include Estradiol Valerate Tablets; Medroxyprogesterone Acetate Tablets; Cabergoline Tablets; Clomiphene Citrate Tablets; Levonorgestrel Tablet; Fluoxymesterone tablets; Liothyronine Sodium tablets; Oxandrolone tablets and others. Its herbal products include Smyle Herbal Toothpaste; Smyle Cough & Sore Throat Reliver and Smyle Mouth Ulcer Gel. Its injectables include Testosterone Cypionate Injection; Methenolone Enanthate Injection; Drostanolone, Testosterone and Trenbolone Inj, and Stanozolol Cypionate Inj.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHAARMASIA LIMITED	+38.81%	4.39M
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+39.08%	621B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.43%	238B
ROCHE HOLDING AG	-0.49%	221B
NOVARTIS AG	+14.47%	218B
AMGEN INC.	+7.42%	166B